Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors

Prakash Jagtap, Csaba Szabo

Research output: Contribution to journalReview articlepeer-review

718 Scopus citations


Poly(ADP-ribose) polymerases (PARPs) are involved in the regulation of many cellular functions. Three consequences of the activation of PARP1, which is the main isoform of the PARP family, are particularly important for drug development: first, its role in DNA repair; second, its capacity to deplete cellular energetic pools, which culminates in cell dysfunction and necrosis; and third, its capacity to promote the transcription of pro-inflammatory genes. Consequently, pharmacological inhibitors of PARP have the potential to enhance the cytotoxicity of certain DNA-damaging anticancer drugs, reduce parenchymal cell necrosis (for example, in stroke or myocardial infarction) and downregulate multiple simultaneous pathways of inflammation and tissue injury (for example, in circulatory shock, colitis or diabetic complications). The first ultrapotent novel PARP inhibitors have now entered human clinical trials. This article presents an overview of the principal pathophysiological pathways and mechanisms that are governed by PARP, followed by the main structures and therapeutic actions of various classes of novel PARP inhibitors.

Original languageEnglish (US)
Pages (from-to)421-440
Number of pages20
JournalNature Reviews Drug Discovery
Issue number5
StatePublished - May 2005
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors'. Together they form a unique fingerprint.

Cite this